Targeting both GLP-1 and GIP receptors to help curb your appetite, make you feel fuller and improve the body's usage of fat stores
GLP-1s have anti-inflammatory effects that help slow these processes, supporting overall health and longevity
The most realistic estimate is 2027, assuming Phase 3 trials produce positive results throughout 2026 and Lilly files for FDA approval in late 2026
Endocrine Reviews, 38(6), 721-745
Chemotherapy-treated mice that received the peptide showed faster restoration of tissue function, lower inflammatory markers, and better physical performance than untreated controls
Patients who develop any of the above symptoms during retatrutide treatment should contact their GP promptly rather than waiting for a scheduled review